Clinical catalyst

How an in-licensed antifungal allowed Amplyx to raise its series B

After in-licensing an antifungal for $1.5 million in January, Amplyx Pharmaceuticals Inc. has used the asset to attract its first venture money in over five years and recruit a new management team focused on product - rather than platform - development. Next up is proving the molecule's undisclosed mechanism confers improvements over

Read the full 520 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE